Juno IND application given FDA nod for leukemia drug candidate JCAR015
Having secured the IND designation, the company now intends to start a multi-center, pivotal Phase II trial soon to evaluate JCAR015 in patients with r/r ALL. Registration of
AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the first-line setting.
Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Scientists at University of Kansas’ Higuchi Biosciences Center laboratories
Healthcare providers will now have the option for either a gluteal or deltoid injection site for administering Abilify Maintena to patients with schizophrenia. Abilify Maintena is the first
Results from the study demonstrated that the trial did not meet its primary endpoint of non-inferiority in overall treatment response in isavuconazole-treated patients at the end of IV